Drug pricing transparency
Drug pricing transparency obligations are reaching into Financial and Capital Markets in ways that most compliance teams did not anticipate two years ago. The U.S. Securities and Exchange Commission's disclosure expectations around material drug pricing exposure, combined with enforcement posture from the U.S. Department of Health and Human Services Office of Inspector General on rebate arrangements, are forcing asset managers and insurers with pharmacy benefit holdings to revisit how pricing risk is characterized in public filings. Short disclosures that once passed review are now drawing comment letters.
Watch
- SEC comment letters targeting drug pricing risk disclosures in 10-K filings
- HHS OIG safe harbor revisions affecting rebate pass-through structures held by financial entities
- Inflation Reduction Act price negotiation outcomes and their downstream effect on portfolio valuations
- State-level pharmacy benefit manager transparency statutes triggering multi-jurisdiction compliance mapping
Recent material activity in Financial & Capital Markets
Active monitoring in place across Financial & Capital Markets. Material developments related to drug pricing transparency will appear here as they are published.